Temporary intraluminal bypass device designed to reduce the rate of diverting stoma and its related complication by at least 70%

The CG-100 device aims to prevent anastomotic leakage in colorectal surgery by creating an internal bypass, improving patient quality of life and reducing healthcare costs significantly.

Subsidie
€ 2.269.312
2022

Projectdetails

Introduction

Anastomotic leakage of colon content into the abdominal cavity is the most devastating complication associated with colorectal surgery. Leaks occur in approximately 22% of cases, leading to increased hospitalization time, higher re-operation rates, increased patient mortality, and additional costs.

Problem Statement

To minimize the risk of a leak, surgeons create a loop of the small bowel which is diverted outside the abdominal wall and connected to a stoma bag to collect the patient’s feces for 4-6 months.

Impact on Patients

  • Diverting stoma significantly diminishes patients’ quality of life.
  • It increases the cost of care.
  • It requires an additional invasive surgery to reverse the stoma.

Solution Overview

Our novel device, CG-100, is an elastic tubular sheath that is positioned at the anastomosis site during the primary colorectal surgery.

Functionality

  • CG-100 creates an internal bypass for all colon content.
  • It is removed non-surgically 10 days after primary surgery.

Expected Outcomes

CG-100 is expected to improve patient quality of life, save approximately 1350 patient lives annually, and reduce healthcare costs by €4 billion per year in the EU.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 2.269.312
Totale projectbegroting€ 3.241.875

Tijdlijn

Startdatum1-6-2022
Einddatum31-5-2025
Subsidiejaar2022

Partners & Locaties

Projectpartners

  • COLOSPAN LTDpenvoerder

Land(en)

Israel

Vergelijkbare projecten binnen EIC Accelerator

EIC Accelerator

A new cardioprotective drug for acute treatment of myocardial infarction

ResoTher aims to validate RTP-026, an immunomodulating therapy, to reduce heart damage and HF risk post-myocardial infarction through Phase II clinical studies.

€ 2.499.999
EIC Accelerator

Clear, scalable and scientific framework to measure terrestrial biodiversity

3Bee leverages IoT, wildlife monitoring, and satellite data to measure and regenerate biodiversity, generating certified Biodiversity Credits for corporations to enhance ESG reporting and brand value.

€ 2.252.714
EIC Accelerator

Novel and Scalable microbial products for REgenerative agriculture

N-Spire aims to revolutionize agriculture by creating a sustainable bioactive fertilizer through innovative manufacturing techniques, enhancing soil health and reducing chemical dependency.

€ 2.499.999
EIC Accelerator

Quantum-based Randomness Processing Units (RPUs) for High-Performance Computation and Data Security

Quside's Randomness Processing Unit (RPU) accelerates stochastic HPC and PQ cryptography by optimizing random workloads, enhancing efficiency and performance across various sectors.

€ 2.499.999

Vergelijkbare projecten uit andere regelingen

EIC Transition

Smart Implant for Magnetic Anastomotic Healing and Leakage Evaluation

The SMARTHEAL project aims to develop a smart magnetic anastomosis implant with integrated micro-sensors for enhanced healing and early detection of leaks, improving surgical outcomes and reducing costs.

€ 2.499.815
MIT Haalbaarheid

TOP Stapler feasibility study

Het project richt zich op het verbeteren van de circulaire stapeltechniek in darmchirurgie om ischemie en necrose te verminderen, wat de genezing en het succes van anastomosen moet bevorderen.

€ 20.000
MIT Haalbaarheid

Implican Stapler

Implican BV ontwikkelt een innovatief apparaat om naadlekkage na darmchirurgie te voorkomen door primaire wondgenezing te bevorderen, met als doel sneller herstel en lagere zorgkosten.

€ 20.000
MIT Haalbaarheid

LAPRIXA: the smallest organ blood pressure measurement device in the world

Corporis Medical onderzoekt de haalbaarheid van het APM-systeem om anastomotische lekkage bij slokdarm- en maagresecties objectief te voorspellen en zo de chirurgische uitkomsten te verbeteren.

€ 20.000